+1 954 427 7179


Why invest with Hormonify?

Established in 1996, Dr. Edward Eckert a world renowned expert in hormone health, specializes in advanced bio-identical hormone replacement therapy (BHRT), weight loss, and natural based remedies for common gynecologic and male hormone replacement therapy.
He has been a leader in hormone replacement therapy and has supervised over one million patients months of therapy.
What makes his therapies so unique and successful is his determination to find a safe, convenient, and effective form of therapy that meets everyone’s needs.
Dr. Eckert discovered that standardized dosing does not meet the patient’s needs, rather, each individual has a specific hormone need.
Therefore, he uses the BHRT concept that mandates specific dosing depending on the individual patient requirements. 

Furthermore, many of the failed therapies rely on the half-truth that BHRT is not FDA approved.
Looking at this misrepresentation closer, each prescription uses 100% FDA approved products.
It is only the specific dosing that has not been specifically studied over time that is and never will be “FDA approved.”
The number of specific dosing combinations in is the millions and will not go through clinical trials on each dosage possible.
It is ludicrous that the same standard does not apply to insulin therapy, or any hormone therapy that is currently used all over the world.
Here at Hormonify Inc., we use only the best compounding pharmacies that undergo strict inspections, regulatory review, and maintain the highest standards of product delivery.

Women’s Health Care Market

According to the BBC Research report, Therapeutics for Women’s Health: Technologies and Global Markets “menopause, post menopause osteoporosis, endometriosis, breast cancer and polycystic ovary syndrome (PCOS) are the most common issues within women’s health and the U.S. women’s health therapeutics market will grow from nearly $19.5 billion in 2015 to $25.3 billion by 2020, rising at compound annual growth rate of 5.4%.”

According to the GBI Research (a provider of industry-leading business intelligence solutions on a global basis) report Women’s Health Therapeutic Market through 2018 “the women’s health therapeutics market is one of the most attractive markets in the global pharmaceutical industry. Hormone therapy, gynecological disorders, and musculoskeletal disorders in women are the prime areas of focus in the women’s health therapeutics market.”

There were approximately 41.7 million women in the United States between the ages of 45 and 64 in 2010, projected to increase slightly (2.8%) to 42.9 million in 2015 and to approximately 44.3 million in 2040, according to the 2010 National Census population figures. These women are the target market for hormone therapy to treat menopause related symptoms.
Hormonify Inc. is seeking investors to expand the company and help treat patients around the world.
Contact us if you would like to learn more about our investment opportunities.
You can do so sending an e-mail at:


or calling us at:


This website may contain forward-looking statements, including information about management’s view of Hormonify Inc.(“the Company”), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Hormonify Inc.